PB-105

N/A

Report date: 2024/11/29 11:23:39

Base Information

Drug NamePB-105
Drug Alias NameLEC/rituximabRituximab biobetter (Pivotal Biosciences)PB105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitorsChemokines replacement
TargetsB-lymphocyte antigen CD20Chemokines
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPivotal Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPivotal Therapeutics
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A